The Day In Review: Biotech Flat As Market Moves Up A Little

December 22, 2004 -- The Centient Biotech 200 was about as flat as it could be today, rising just 3.1 points (.09%) to 3546.72, while the NYSE Composite and Nasdaq both added on about .3%. Trading was active through the early part of the day, but declined as the session wore on and the upcoming holidays began to make themselves felt. We discuss a new FDA approval for Santarus, the price for Eyetech's Macugen, a new indication for J&J's Remicade, and Lilly's restructuring charge...

Back to news